LENZ Therapeutics Stock Is Attractive Before PDUFA

I covered LENZ Therapeutics, Inc. (NASDAQ: LENZ ) in August, and since then, the company has progressed steadily towards its first approval. In August, I called LENZ a BUY, and while the stock nearly doubled in November, it is now down to onlyAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research ...